

Press Release

February 17, 2025

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Selected as Highest Rating A-List Company by CDP in the Category of Climate Change in CDP 2024

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) announced today that it has been selected by CDP, a global environmental non-profit organization, as the highest A-List company in the category of "climate change" in CDP 2024, in recognition of its efforts and measures against climate change.



Sumitomo Pharma Group defines the practice of its Mission, "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," that contributes to the realization of a sustainable society and leads to the sustained enhancement of its corporate value as "Sustainability Management," and has set "Promotion of environmental initiatives" as one of our Material Issues for our Sustainability Management.

Environmental issues such as climate change are serious global problems that threaten the health and wellbeing of people worldwide. Sumitomo Pharma Group will continually contribute to solving these problems through reducing GHG emissions and other environmental initiatives as well as to realizing a sustainable society, thereby enhancing sustained corporate value.

About CDP

CDP is a global non-profit that runs the world's only independent environmental disclosure system. Partnering with leaders in enterprise, capital, policy and science, we surface the information needed to enable Earth-positive decisions. We helped more

than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Please visit https://www.cdp.net/en to find out more.

Contact:

Corporate Communications,

Global Finance

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp